Your challenges
High-purity water plays a critical role in pharmaceutical and life science manufacturing. Meeting quality requirements while maintaining efficient and reliable operations can be complex.
Meeting stringent pharmaceutical water quality standards
Producing Purified Water and Water for Injection requires compliance with strict regulatory standards such as USP, Ph. Eur, and JP. Maintaining consistent water quality is critical for protecting product integrity and ensuring patient safety.
Ensuring reliable water supply for critical production processes
Water is a vital utility throughout pharmaceutical production. Unplanned interruptions or inconsistent water quality can impact manufacturing schedules and operational performance.
Reducing operational and energy costs
As facilities seek to improve efficiency, water purification systems must deliver high-quality water while minimizing energy consumption, maintenance requirements and operational costs.
Supporting compliance and sustainability goals
Manufacturers face increasing pressure to meet regulatory requirements while reducing their environmental footprint. Water treatment solutions must support both compliance and responsible resource management.
How does it work?
Our process
Feedwater first passes through a pretreatment stage to protect the downstream purification system and ensure stable operation. The water is then processed through reverse osmosis and continuous electorde ionization, removing dissolved salts, organics, microorganisms and other contaminants to produce high-purity water.
The purified water is stored and distributed through a fully integrated system designed to maintain water quality and support reliable operation.
By combining advanced membrane technologies in a compact solution, the TORRENT™ consistently delivers Purified Water (PW) and Water for Injection (WFI) that meet the stringent requirements of pharmaceutical and life science applications.
Key figures
Up to 85%
Nominal water recovery
Up to 100%
Water recovery in conservation mode
3 pharmacopeias
Exceeds USP, Ph. Eur., and JP requirements
Triple membrane barrier
Additional protection for WFI production